Small molecule hobbles dengue in vitro and in vivo

A novel compound inhibits dengue virus, as well as other closely related important human pathogens. The research is published in the September 2011 issue of the journal Antimicrobial Agents and Chemotherapy.

Dengue virus causes an estimated about 50 million infections annually, resulting in half a million hospitalizations, and a 2.5 percent mortality rate, according to the . Neither antivirus therapy nor vaccines exist against dengue. The newly discovered inhibitor is also active against fellow flavivirus family members including , yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. The compound works by preventing translation of RNA to protein, according to the report.
 
In the study, the researchers identified the small molecule inhibitor via high throughput screening of Novartis compound libraries, says corresponding author, Pei-Yong Shi of Novartis Institute for Tropical Diseases, Singapore. They then refined the original molecule to give it greater metabolic stability. Tests in a dengue mouse viremia model showed that “this compound significantly reduced peak viremia, demonstrating the in vivo efficacy of the inhibitor,” according to the report.
 
However, despite the fact that the compound selectively inhibits protein translation in flaviviruses, in in vitro tests, it nonselectively inhibited viral and host translation. That raised the specter of side effects, and indeed, tripling the experimental dose in the mouse model caused significant side effects, according to the report. Thus, the therapeutic window needs to be widened before the compound will be ready for clinical testing, the researchers report.
 
The compound is being developed under the auspices of the Novartis Institute for Tropical Diseases, which aims to develop novel therapeutics for neglected diseases, and to provide these new medicines to poor patients at cost prices,” says Shi. “Dengue poses a public health threat to 2.5 billion people worldwide,” most of them living in poverty or near poverty.

More information: Q.-Y. Wang, et al. 2011. A translation inhibitor that suppresses dengue virus in vitro and in vivo. Antim. Agents Chemother. 55:4072-4080

Provided by American Society for Microbiology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Team uncovers dengue fever virus' molecular secrets

Mar 08, 2011

Researchers at the Instituto de Medicina Molecular in Lisbon, Portugal and the Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, are making major strides toward understanding the life cycle of flaviviruses, ...

New West Nile and Japanese encephalitis vaccines produced

May 30, 2008

University of Texas Medical Branch at Galveston researchers have developed new vaccines to protect against West Nile and Japanese encephalitis viruses. The investigators created the vaccines using an innovative technique ...

Recommended for you

Families wait in agony for word on Ebola patients

1 hour ago

First the ring tone echoed outside the barbed-wire-topped walls of the Ebola clinic. Then came the wails of grief, as news spread that 31-year-old Rose Johnson was dead just days after she was brought here ...

China to open first high security bio laboratory

1 hour ago

China's first high-security biosafety laboratory will be ready for use by December, in a move hailed as a "crucial" moment in the fight against pathogens such as the Ebola virus, officials said Tuesday.

US Ebola labs, parts for clinic arrive in Liberia

3 hours ago

U.S. mobile Ebola labs should be up and running in Liberia this week, and American troops have broken ground for a field hospital, as the international community races to increase the ability to care for ...

Ebola-hit Liberia staring into the abyss

7 hours ago

With its collapsed health service, sick and poorly equipped security forces and broken economy, Ebola-hit Liberia finds itself on the brink of complete societal breakdown, experts warn.

User comments